Original news and analysis on international IP policy
BANGKOK - The European Union told Asian countries Thursday that protecting geographical indications of their products would benefit their poor, rural people as the EU is offering to renew its intellectual property cooperation with regional countries with GI enforcement as a greater element.
BRUSSELS - India’s status as a top world supplier of generic medicines could be threatened by a free trade agreement its government is negotiating with the European Union, a new study has concluded. Separately, the World Customs Organization has abandoned its intellectual property rights enforcement group, replacing it with a non-policymaking information committee.
A final decision on a World Trade Organization case over intellectual property rights protection between China and the United States was accepted by the states Friday, with both claiming its arbiter had affirmed their positions.
The World Health Organization on Friday issued a statement on a high-profile debate over Dutch customs authorities’ delays of shipments of legitimate generic pharmaceuticals passing through the European country on their way to patients in developing countries. The goods were apparently believed to be counterfeit medicines.
Should national drug control bodies grant marketing licences to generic medicine companies only if their products do not possibly infringe existing patent rights? Yes, German pharmaceutical company Bayer told the High Court of Delhi last week when the court heard arguments in an ongoing court case on patent linkage.
布鲁塞尔 - 全球公共卫生活跃分子声称，欧盟执意要在一系列自由贸易协议中添加有关医药专利的强硬规定将会妨害发展中国家获得医药。
ابروكسل- إن الجهود التي يبذلها الاتحاد الأوروبي لإدراج أحكام حول براءات المستحضرات الصيدلانية في سلسلة من اتفاقات التجارة الحرة التي يتفاوض حولها قد تشكل تهديدا على إمكانية الحصول على الأدوية في البلدان النامية، على حد قول الناشطين في مجال الصحة العامة على الصعيد العالمي.
BRUXELLES - Selon certains activistes de la santé publique mondiale, les efforts de l’Union européenne (UE) pour intégrer des dispositions sur les brevets pharmaceutiques dans un certain nombre d’accords de libre échange en cours de négociation pourraient mettre en péril l’accès aux médicaments dans les pays en développement.
BRUSELAS- Los esfuerzos de la Unión Europea para introducir disposiciones firmes en materia de patentes farmacéuticas en una serie de acuerdos de libre comercio que está negociando podrían poner en peligro el acceso a los medicamentos en los países en desarrollo, según han afirmado activistas de la salud pública a nivel mundial.
BRUSSELS - Efforts by the European Union to insert strong provisions on pharmaceutical patents in a series of free trade agreements it is negotiating could imperil access to medicines in developing countries, global public health activists have alleged.
As part of trade talks being conducted with India, Colombia, Peru and a regional grouping in south-east Asia, EU officials have proposed that drug-makers should benefit from a robust intellectual property regime. National regulatory authorities in the countries concerned would be prevented for lengthy periods from using data provided by a company that holds a drug patent in order to authorise a generic version of that medicine.
By Catherine Saez Publicly funded research institutions are major players in the area of life sciences and policies on the management of intellectual property emanating from this research have to be defined, according to speakers at a recent symposium in…
By Jia Hepeng and Yuan Yue for Intellectual Property Watch BEIJING – China’s newly revised patent law could create a more favourable environment for foreign companies to do research in the country, though measures are still needed to implement the…